Subscribe
Models
HUGO Series 🌟
Cell Line Models
Services
Preclinical Efficacy
Resources
About Us
TG-hATXN3 (85Q) Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
TG-hATXN3 (85Q) Mouse
Product Name
TG-hATXN3 (85Q) Mouse
Product ID
C001397
Strain Name
C57BL/6JCya-Tg(hATXN3*85Q)/Cya
Backgroud
C57BL/6JCya
Status
When using this mouse strain in a publication, please cite “TG-hATXN3 (85Q) Mouse (Catalog C001397) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Basic Information
Validation Data
Related Resource
Basic Information
Gene Name
ATXN3
Gene Alias
AT3, JOS, MJD, ATX3, MJD1, SCA3
NCBI ID
Chromosome
Chr 14 (Human)
MGI ID
Datasheet
Strain Description
The ATXN3 gene encodes Ataxin 3, a protein primarily responsible for intracellular protein degradation and involved in various cellular processes including DNA repair and autophagy. The ATXN3 gene is widely expressed in the human brain and other tissues, with particularly high expression levels in the cerebellum and spinal cord [1]. Spinocerebellar Ataxia type 3 (SCA3), also known as Machado-Joseph Disease (MJD), is a progressive neurodegenerative disorder characterized clinically by motor coordination impairment (cerebellar ataxia), bulbar, pyramidal, and extrapyramidal dysfunction, and may be accompanied by peripheral neuropathy or ophthalmoplegia [2]. SCA3 is the most common dominantly inherited ataxia, caused by an abnormal expansion of CAG repeat sequences in the ATXN3 gene. This expansion leads to the formation of an elongated polyglutamine (polyQ) domain in the Ataxin 3 protein, subsequently causing protein aggregation and dysfunction of the ubiquitin-proteasome system. Among polyglutamine diseases, the prevalence of SCA3 is second only to Huntington's disease (HD). The number of CAG repeats in the ATXN3 gene of healthy individuals typically ranges from 12 to 44, whereas affected individuals with SCA3 have 56 to 87 repeats. Individuals with 45 to 55 repeats may exhibit incomplete penetrance of SCA3 symptoms. Similar to other polyglutamine diseases, the length of the CAG repeat is negatively correlated with the age of onset and positively correlated with the severity of SCA3 [2-3].
This strain represents a SCA3 disease model generated through transgenic technology, expressing a human ATXN3 gene carrying approximately 85 CAG repeats (Q). The number of CAG repeats (Q) in the human ATXN3 gene in this model is associated with the more severe forms of SCA3. Preliminary research data indicate that 2-month-old TG-hATXN3(85Q) mice exhibit a significant increase in stride width and a shortened latency to fall in the rotarod test, suggesting impairments in motor coordination and activity. Therefore, this strain can be utilized for research on the ubiquitin-proteasome system and the pathogenic mechanisms of SCA3, as well as for the screening, development, and evaluation of targeted therapeutic drugs.
Reference
Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, Shimazaki H, Soutome M, Endo K, Ohta S, et al. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet. 1993 Jul;4(3):300-4.
Paulson H. Machado-Joseph disease/spinocerebellar ataxia type 3. Handb Clin Neurol. 2012;103:437-49.
McLoughlin HS, Moore LR, Paulson HL. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol Dis. 2020 Feb;134:104635.
Strain Strategy
The mouse model was generated through transgenic (TG) technology by integrating a human ATXN3 gene carrying approximately 85 CAG repeats (Q) into the mouse genome.
Application Area
Research on the ubiquitin-proteasome system and the pathological mechanisms of SCA3;
Screening, development, and evaluation of therapeutic drugs for SCA3.
Validation Data
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

